In a report released today, Laura Chico from Wedbush maintained a Buy rating on Viridian Therapeutics, with a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laura Chico’s rating is based on several key factors that highlight Viridian Therapeutics’ promising future prospects. The company’s development timelines are progressing as planned, with the veligrotug Biologics License Application (BLA) expected to be completed by the second half of 2025, setting the stage for a potential U.S. launch in the latter half of 2026. Additionally, the pivotal VRDN-003 studies are on track for data readouts in the first half of 2026, which could further bolster the company’s position.
Furthermore, Viridian’s financial standing is solid, with a cash runway extending into the second half of 2027, supported by a $70 million upfront payment from a collaboration with Kissei Pharma. The removal of an assumed secondary offering and an increase in research and development and selling, general, and administrative expenses also contribute to a favorable outlook. These elements, combined with the attractive valuation of the stock, underpin the Buy rating, as the company is well-positioned for significant developments in 2026.
Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Jade Biosciences, and BioCryst. According to TipRanks, Chico has an average return of 4.6% and a 44.92% success rate on recommended stocks.